# Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

> **NCT01833065** · PHASE3 · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 314 (actual)

## Conditions studied

- Chronic Idiopathic Constipation

## Interventions

- **DRUG:** Elobixibat 10 mg/day
- **DRUG:** Elobixibat 5 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01833065
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 314 (ACTUAL)
- **Why stopped:** Terminated due to a distribution issue with the trial medication
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833065, "Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01833065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*